Bad Blood
10,99 €
Kopen bij Amazon Bekijk in Apple BooksLiever op papier? Alle uitvoeringen bij Amazon →
Prijs in Apple Books. Bij Amazon kan die afwijken.
- Ook als luisterboek
- Bad Blood: Secrets and Lies in a Silicon Valley Startup (Unabridged)
- Verschenen
In andere talen: Bad Blood: Secrets and Lies in a Silicon Valley Startup (Unabridged) · Engels Bad Blood · Portugees Ont blod : hemligheter och lögner i Silicon Valley · Duits Ont blod : hemligheter och lögner i Silicon Valley · Frans Ont blod : hemligheter och lögner i Silicon Valley · Zweeds
In de lijsten
| Positie | Beste | Dagen | |
|---|---|---|---|
| Kleine onderneming en ondernemerschap | #9 | #23 | 6 |
Voor auteurs: zet deze badge op je website
Kopieer deze code naar je website of blog:
Beschrijving
NATIONAL BESTSELLER • The gripping story of Elizabeth Holmes and Theranos—one of the biggest corporate frauds in history—a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword covering her trial and sentencing, bringing the story to a close.
“Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times Book Review
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.
“Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times Book Review
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.